New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nuclear Medicine and Biology |
Vol/bind | 39 |
Udgave nummer | 7 |
Sider (fra-til) | 962-9 |
Antal sider | 8 |
ISSN | 0969-8051 |
DOI | |
Status | Udgivet - okt. 2012 |
ID: 45945376